Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · Neurodegeneration biomarkers and longitudinal studies

Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysis.

Jonathan M Wilson; Jeffrey L Dage; Hui-Rong Qian; Courtney L Irelan; Hannah S Crowder; Kevin L Duffin; Mark Mintun; Dawn A Brooks; Hertzel C Gerstein; M Angelyn Bethel

Originally published in Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026-04-01

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

Introduction This post hoc analysis of the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial examined associations between dulaglutide, Alzheimer's disease and related dementia (ADRD) biomarkers, and substantive cognitive impairment (SCI). Methods Participants (dulaglutide, n = 3741; placebo, n = 3627) completed cognitive tests and provided blood samples at baseline and 2 years, with additional cognitive tests at 5-year and final visits. Analysis of covariance and Cox models tested associations between dulaglutide, SCI, and plasma neurofilament light chain (NfL), phosphorylated tau217 (p-tau217), and glial fibrillary acidic protein (GFAP) biomarkers. Results Dulaglutide-associated changes in biomarkers or SCI were nonsignificant overall. Participants with NfL ≥56 pg/mL had a dulaglutide-associated 2-year reduction in NfL (-27.4% vs -14.2%; p = 0.003). Participants with p-tau217 ≥25 pg/mL had a dulaglutide-associated SCI reduction (hazard ratio = 0.78; p = 0.0064). Discussion Dulaglutide reduced NfL and SCI in participants with select elevated plasma ADRD biomarkers, with limited 2-year effects on p-tau217 and GFAP.

DISCUSSION

This unique study characterized relevant ADRD biomarkers in a large longitudinal trial with associated outcomes and endpoints, providing insights into the effect of dulaglutide treatment on ADRD biomarkers. The three plasma biomarkers included in this study were previously shown to be associated with the progression of neurodegenerative diseases. Incretin‐based therapies, such as glucagon‐like peptide‐1 receptor agonists, have shown promising effects on neurodegenerative pathways, 35 , 36 , 37 , 38 , 39 and this study has provided a novel way to examine these effects.

Editorial reading guide

  • Was the evidence cross-sectional, longitudinal or experimental?
  • How did the authors account for age, disease stage and differences among participants?